American Society of Hirudotherapy

The role of the insertion loop around tryptophan 148 in tthe activity of thrombin

Research article published in Biochemistry (1996)

Last Updated: November 1, 2026ASH Editorial · based on the books
Research article — evidence review: Off-label use means application outside the FDA-cleared indication. Clinical evidence (RCTs or systematic reviews) supports this use, but the FDA has not cleared it.Article reference: Content describes science, methodology, or organizational reference material — not a clinical efficacy claim.
Evidence: In vitro / laboratoryDrug DevelopmentSalivary PharmacologyDiBella et al. · Biochemistry, 1996

Abstract

Thrombin has trypsin-like specificity for Arg-Xaa and Lys-Xaa peptide bonds; however, it is much more specific than trypsin, cleaving far fewer peptide bonds in macromolecular substrates. To probe the nature of the specificity of thrombin, a mutant has been constructed in which the Trp148 loop of thrombin has been replaced with the same loop of bovine trypsin. This mutant was expressed in Escherichia coli as prethrombin-2(148) using a T7 expression system previously described for wild-type prethrombin-2 [DiBella et al. (1995) J. Biol. Chem. 270, 163-169]. After refolding and purification, prethrombin-2(148) was activated to thrombin(148) with Echis carinatus snake venom. The k(cat)/K(m) for the release of fibrinopeptide A from fibrinogen was 4.5 +/- 0.5 microM(-1)s(-1) for thrombin(148), which was approximately 20% of that of recombinant thrombin (25 +/- 2.0 microM(-1)s(-1)). Thrombin(148) was inhibited less well by hirudin with a K(i) of 500 pM compared to a value of 12 pM determined for recombinant thrombin. The mutant thrombin was also compared to trypsin and wild-type recombinant thrombin for the ability to cleave small peptide substrates. The Michaelis constants (K(m)) were found to be between 5- and 10-fold higher for thrombin(148) relative to wild-type recombinant thrombin, although the catalytic constants (k(cat)) for thrombin(148) and recombinant thrombin remained relatively unchanged for all three substrates. Thrombin(148) had a specificity constant (k(cat)/K(m)) 2-fold higher for the hydrolysis of H-D-phenyalanyl-L- pipecolyl-L-arginine-p-nitroaniline (a thrombin substrate) than that of trypsin. For N-benzoyl-L-isoleucyl-L-glutamylglycyl-L-arginine- p-nitroaniline (a trypsin substrate) and N-carbobenzoxyglycylprolyl-L-arginine-p-nitroaniline (a substrate for both enzymes), the specificity constants for trypsin were 1000- and 16-fold higher, respectively. Although replacement of the Trp(148) loop does not yield an enzyme with more trypsin-like specificity, the Trp(148) loop is important in the substrate binding and specificity of thrombin (on the basis of K(m) and K(i)).

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleResearch Support, U.S. Gov't, P.H.S.
Indexed MeSH termsAmino Acid SequenceAnimalsBase SequenceBinding SitesCattleDNAEnzyme PrecursorsEscherichia coliIn Vitro TechniquesKineticsModels, MolecularMolecular Sequence DataMutagenesis, Site-DirectedOligopeptidesProtein ConformationProthrombinRecombinant ProteinsSubstrate SpecificityThrombinTrypsinTryptophan

Summary

Replacing thrombin's Trp148 loop with the trypsin equivalent reduced fibrinogen cleavage to about 20% of wild type and weakened hirudin inhibition (Ki 500 pM versus 12 pM), showing this loop shapes thrombin's substrate binding and specificity.

Why This Matters for Hirudotherapy

DiBella et al. (1996, Biochemistry) probed thrombin's substrate specificity by engineering a mutant in which thrombin's Trp148 insertion loop was replaced with the corresponding loop of bovine trypsin; the mutant retained thrombin-like specificity overall but showed altered kinetics, and notably was inhibited far less well by hirudin (Ki ~500 pM) than recombinant thrombin (Ki ~12 pM), implicating the Trp148 loop in substrate binding and specificity. This is foundational biochemistry behind the leech anticoagulant story: hirudin, the medicinal leech's signature thrombin inhibitor, is used here as a molecular probe, and the sharp loss of inhibition with the loop swap helps map how hirudin recognizes and blocks thrombin — the basis of leech-derived anticoagulation. Honest caveat: this is an in-vitro enzymology/protein-engineering study using recombinant proteins, not a clinical or even animal investigation of hirudotherapy, and the hirudin data are a mechanistic readout rather than evidence of therapeutic effect.

Citation

Reference (Vancouver style)

DiBella EE, Scheraga HA. The role of the insertion loop around tryptophan 148 in tthe activity of thrombin. Biochemistry. 1996;35(14):4427-4433. doi:10.1021/bi952617c. PMID: 8605192

Bibliographic details (authors, volume, pages, DOI) are taken from the PubMed record.

Added to ASH library: May 28, 2026 · Site last updated: November 1, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.